---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066376"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:48:56.516932+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data

## Summary
- Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.
- Cash & short-term investments $285.4M at Mar 31, 2025 (down from $305.3M Dec 31, 2024); runway through end of 2026.
- RAP-219 Phase 2a refractory focal epilepsy topline results expected Q3 2025.
- RAP-219 Phase 2a bipolar mania trial to start Q3 2025; topline data expected H1 2027.
- Dr. Jeffrey Sevigny appointed CMO; Investor & Analyst Day scheduled June 2, 2025.

## SEC filing metadata
- accession: 0000950170-25-066376
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/0000950170-25-066376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/rapp-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066376
- JSON: https://secwatch.observer/filing/0000950170-25-066376.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.